


## AMENDMENTS TO THE CLAIMS




This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Original) A compound represented by the formula (I)



wherein

A is a group represented by the following formula (A1), (A2) or (A3)



B is a 1H-tetrazol-5-yl group or a 2,4-dioxothiazolidin-5-yl group,

X is methylene, an oxygen atom or a sulfur atom,

Y is a single bond or a C6-10 arylene group,

R<sup>1A</sup> is a hydrogen atom or a C1-6 alkyl group,

R<sup>2A</sup> and R<sup>3A</sup> are the same or different and each is a hydrogen atom, a carboxyl group or a C1-6 alkyl group,

R<sup>4A</sup>, R<sup>5A</sup> and R<sup>6A</sup> are the same or different and each is a hydrogen atom or a C1-6 alkyl group, and

R<sup>7A</sup> is a C1-10 alkyl carbonyl group,

provided that when A is (A2), then B should be a 2,4-dioxothiazolidin-5-yl group,

or a pharmacologically acceptable salt thereof or an ester thereof.

2. (Original) The compound of claim 1, wherein B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

3. (Previously Presented) The compound of claim 1, wherein Y is a C6-10 arylene group, or a pharmacologically acceptable salt thereof or an ester thereof.


4. (Previously Presented) The compound of claim 1, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

5. (Original) The compound of claim 1, wherein B is a 2,4-dioxothiazolidin-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

6. (Original) The compound of claim 1, wherein A is a group represented by (A1), and B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

7. (Original) The compound of claim 1, wherein A is a group represented by (A2), and B is a 2,4-dioxothiazolidin-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

8. (Original) A compound represented by the formula (IA3)



(IA3)

wherein

B is a 1H-tetrazol-5-yl group or a 2,4-dioxothiazolidin-5-yl group,

Y is a single bond or a C6-10 arylene group, and

R<sup>7A</sup> is a C1-10 alkyl carbonyl group,

or a pharmacologically acceptable salt thereof or an ester thereof.

9. (Original) The compound of claim 8, wherein B is a 1H-tetrazol-5-yl group, or a pharmacologically acceptable salt thereof or an ester thereof.

10. (Original) A compound selected from the group consisting of 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-pentanoylamino]benzoic acid, 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-butanoylamino]benzoic acid, 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-heptanoylamino]benzoic acid, 2-oxo-3-propyl-1-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-trihydroquinoline-7-carboxylic acid and 5-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1,3-thiazolidine-2,4-dione, or a pharmacologically acceptable salt thereof or an ester thereof.

11. (Original) 3-[N-[4-(2,4-Dioxothiazolidin-5-yl)benzyl]-N-pentanoylamino]benzoic acid, 3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-octanoylamino]benzoic acid, or a pharmacologically acceptable salt thereof or an ester thereof.

12. (Currently Amended) A medicament comprising the compound of ~~claim 4~~ claim 5, or a pharmacologically acceptable salt thereof or an ester thereof.

13. (Previously Presented) An inhibitor of AGEs formation, which comprises the compound of claim 5, or a pharmacologically acceptable salt thereof or an ester thereof.

14. (Previously Presented) A pharmaceutical composition for the prophylaxis or treatment of diabetic complication, which comprises the compound of claim 5, or a pharmacologically acceptable salt thereof or an ester thereof.

15. (Previously Presented) A pharmaceutical composition for the prophylaxis or treatment of diabetic nephropathy, which comprises the compound of claim 5, or a pharmacologically acceptable salt thereof or an ester thereof.

16.– 19. (Canceled)

20. (Previously Presented) A method of inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 5, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

21. (Previously Presented) A method of preventing or treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 5, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

22. – 25. (Canceled)

26. (Previously Presented) The compound of claim 2, wherein Y is a C6-10 arylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

27. (Previously Presented) The compound of claim 2, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

28. (Previously Presented) The compound of claim 3, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

29. (Previously Presented) The compound of claim 26, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or an ester thereof.

30. (Previously Presented) An inhibitor of AGEs formation, which comprises the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof.

31. (Previously Presented) A pharmaceutical composition for the prophylaxis or treatment of diabetic complication, which comprises the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof.

32. (Previously Presented) A pharmaceutical composition for the prophylaxis or treatment of diabetic nephropathy, which comprises the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof.

33. (Previously Presented) A method of inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

34. (Previously Presented) A method of preventing or treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof, to the warm-blooded animal.

35. (New) A medicament comprising the compound of claim 7, or a pharmacologically acceptable salt thereof or an ester thereof.